iX Biopharma (SGX:42C) Gross-Profit-to-Asset % : 5.47% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. iX Biopharma's annualized Gross Profit for the quarter that ended in Dec. 2023 was S$1.18 Mil. iX Biopharma's average Total Assets over the quarter that ended in Dec. 2023 was S$21.62 Mil. Therefore, iX Biopharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 5.47%.

iX Biopharma Gross-Profit-to-Asset % Historical Data

The historical data trend for iX Biopharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma Gross-Profit-to-Asset % Chart

iX Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

-1.77

-2.69

-2.13

51.89

8.68

iX Biopharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															88.24	1.01	6.55	11.27	5.47

Competitive Comparison of iX Biopharma's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iX Biopharma's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where iX Biopharma's Gross-Profit-to-Asset % falls into.

iX Biopharma Gross-Profit-to-Asset % Calculation

iX Biopharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2023 )	/	( (Total Assets (A: Jun. 2022 )	+	Total Assets (A: Jun. 2023 ))	/ count )
	=	2.32	/	( (28.517	+	24.928)	/ 2 )
	=	2.32	/	26.7225
	=	8.68 %

iX Biopharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	1.182	/	( (24.928	+	18.309)	/ 2 )
	=	1.182	/	21.6185
	=	5.47 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

iX Biopharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of iX Biopharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma (SGX:42C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma (SGX:42C) Headlines

No Headlines